Germany's Merck KGaA said on Tuesday its lab equipment division and its pharmaceuticals division would be under new ...

Jean-Charles Wirth and Danny Bar-Zohar are set to assume the life science and healthcare CEO roles respectively.

The latest example of this trend is Merck KGaA’s impending all-cash acquisition of SpringWorks Therapeutics, valued around ...

Robi, 30, was vaccinated with Gardasil as a teenager and claims the shot led to impaired mobility that confined her to a ...

Hard on the heels of the disclosure that Merck KGaA is talking to SpringWorks about a possible takeover, a new FDA approval could have sweetened the deal. Stamford, Connecticut-based SpringWorks ...

Shares of Merck & Co. Inc. MRK rallied 2.08% to $89.50 Friday, on what proved to be an all-around rough trading session for ...

(Reuters) - Merck and a woman suing the drugmaker agreed to halt a trial over alleged injuries from the drugmaker's human ...

Merck (MRK) and a woman suing the company have agreed to pause a trial over alleged injuries linked to its human papillomavirus vaccine, a case ...

“We are very impressed with Syngene’s professionalism, commitment to scientific excellence, and ability to deliver high-quality work on time,” said Allan Wehnert, CEO & Founder of Orocidin. “This ...

Germany’s Merck KGaA has signed a collaboration with Tencent ... and reforms from the country’s drugs regulator to make it faster at approving new medicines, will drive development of the ...

thyssenkrupp nucera AG & Co. KGaA (ETR:NCH2) defied analyst predictions to release its first-quarter results, which were ahead of market expectations. thyssenkrupp nucera KGaA delivered a ...

Revenue: €229.8m (down 1.0% from 1Q 2024). Net income: €28.9m (down 35% from 1Q 2024). Profit margin: 13% (down from 19% in 1Q 2024). The decrease in margin was primarily driven by higher ...